Management of Hemato-oncology children during covid-19 crisis

Ranjit Kumar C S (1) , Reghu K Sukumaran (2) , Anil Aribandi (3) , Ashok Kumar K (4) , Arun Kumar Lingutla (5) , Krishnamani K V (6)
(1) Department of Pediatric Hemato-Oncology, American Oncology Institute, Hyderabad -500019, India, India ,
(2) Department of Hematology-Oncology, Tata Medical Center, Kolkata -700160, India, India ,
(3) Department of Hemato-Oncology, American Oncology Institute, Hyderabad -500019, India, India ,
(4) Department of Hemato-Oncology, American Oncology Institute, Hyderabad -500019, India, India ,
(5) Department of Medical Oncology, American Oncology Institute, Hyderabad -500019, India, India ,
(6) Department of Medical Oncology, American Oncology Institute, Hyderabad -500019, India, India

Abstract

The Coronavirus (COVID-19) caused by severe acute respiratory syndrome, coronavirus 2(SARS-CoV-2). The COVID-19 pandemic has had a catastrophic effect on global health. About 2% of confirmed cases of COVID-19 were among children aged<18yrs old. Children, teens and young adults are at higher risk for severe complication and presentation with multisystem inflammatory disease. Management of children with COVID infection is not yet standardized. However, cancer children are at potential risk due to immunocompromised status and their management is unknown. The immunocompromised children are at risk of severe infection, and they have a high mortality rate. Here in this article, we are describing when to suspect COVID infection, how to manage newly diagnosed cancer children and existing patient including bone marrow transplantation and immunosuppression therapy and also blood transfusion policy during COVID pandemic time.

Full text article

Generated from XML file

Authors

Ranjit Kumar C S
cs.ranjith@gmail.com (Primary Contact)
Reghu K Sukumaran
Anil Aribandi
Ashok Kumar K
Arun Kumar Lingutla
Krishnamani K V
Ranjit Kumar C S, Reghu K Sukumaran, Anil Aribandi, Ashok Kumar K, Arun Kumar Lingutla, & Krishnamani K V. (2020). Management of Hemato-oncology children during covid-19 crisis. International Journal of Research in Pharmaceutical Sciences, 11((SPL 1), 369–375. Retrieved from https://ijrps.com/home/article/view/1476

Article Details

No Related Submission Found